Investment analysts at StockNews.com initiated coverage on shares of Agenus (NASDAQ:AGEN – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the company. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $8.30 price objective on shares of Agenus in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Agenus in a report on Tuesday, February 28th. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat, Agenus presently has an average rating of “Moderate Buy” and a consensus price target of $7.10.
Agenus Price Performance
Shares of AGEN stock opened at $1.70 on Thursday. The stock has a market cap of $518.18 million, a P/E ratio of -2.15 and a beta of 1.50. Agenus has a one year low of $1.25 and a one year high of $3.37. The stock has a fifty day moving average price of $2.27 and a 200 day moving average price of $2.44.
Institutional Trading of Agenus
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.